J Liver Cancer.  2022 Sep;22(2):91-92. 10.17998/jlc.2022.09.20.

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?

• Lee HW

• KMID: 2534235
• DOI: http://doi.org/10.17998/jlc.2022.09.20

Reference

1. Ahn YH, Lee H, Han JE, Cho HJ, Cheong JY, Park B, et al. Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. J Liver Cancer. 2022; 22:125–135.

2. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; 65:719–726.

3. Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA initiation after curative treatment and its relationship with the recurrence of HCV-related HCC. J Hepatocell Carcinoma. 2020; 7:347–360.

4. Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019; 156:2149–2157.

5. Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug treatment for chronic hepatitis C infection and cancer risk. Dtsch Arztebl Int. 2017; 114:597–602.

6. Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, et al. Hepatocellular carcinoma survival by etiology: a SEERmedicare database analysis. Hepatol Commun. 2020; 4:1541–1551.

7. Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, et al. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022; 128:3470–3478. 2021;27:236-245.